A Phase I/II Trial of BMS-754807 in Combination With Cetuximab (Erbitux®) in Subjects With Advanced or Metastatic Solid Tumors
For additional information, please contact the BMS oncology clinical trial information
service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit
www.BMSStudyConnect.com for more information on clinical trial participation.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose of BMS-754807 administered orally (daily schedule) in combination with cetuximab administered standard doses IV (weekly basis) will be determined by observation of dose limiting toxicities during the first 33 days of administration
During and at the end of the first 33 days after the first dose of BMS-754807 is given
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA191-006
NCT00908024
October 2009
December 2012
Name | Location |
---|---|
Duke University Medical Center | Durham, North Carolina 27710 |
Nebraska Methodist Hospital | Omaha, Nebraska 68114 |
University of Wisconsin | Madison,, Wisconsin 53792-5666 |